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Abstract
Background: The chromosome 3q29 microdeletion syndrome is characterized by a clinical phenotype that
includes behavioral features consistent with autism and attention deficit hyperactivity disorder, mild to moderate
developmental delay, language-based learning disabilities, and/or dysmorphic features. In addition, recent data
suggest that adults with chromosome 3q29 microdeletions have a significantly increased risk for psychosis and
neuropsychiatric phenotypes.
Case presentation: We report a 3-year-old male with global developmental delay, anemia, and mild dysmorphic
facial features. Clinical chromosomal microarray (CMA) testing of the proband detected a heterozygous 1.21 Mb
deletion at chromosome 3q29, consistent with a diagnosis of the 3q29 microdeletion syndrome. Interestingly,
subsequent parental testing determined that the pathogenic deletion was inherited from his otherwise healthy
mother who had a history of learning disabilities. The chromosome 3q29 microdeletion was not detected in the
healthy older sibling of the proband by CMA testing, nor was it prenatally detected in a subsequent maternal
pregnancy.
Conclusion: Our report highlights the 3q29 microdeletion syndrome as an illustrative example of the importance
of a molecular diagnosis for families that harbor pathogenic copy number aberrations with variable expressivity, in
particular those that also impart an increased risk for adult onset neuropsychiatric phenotypes.
Keywords: 3q29 microdeletion, Developmental disabilities, Neuropsychiatric phenotypes familial inheritance,
Copy number variation

Background
Chromosomal microarray (CMA) testing offers a powerful
approach to detect submicroscopic copy number changes
in the human genome [1, 2], which has led to the discovery of several microdeletion and microduplication
syndromes [3, 4]. Moreover, clinically-relevant intragenic
copy number changes are now also being discovered by
large-scale genome sequencing efforts [5–7]. Importantly,
some of these syndromes have incomplete penetrance
and/or variable expressivity, which often result in
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nonspecific neurodevelopmental clinical features and
challenging clinical diagnoses. The chromosome 3q29
microdeletion syndrome is characterized by a clinical
phenotype that can include behavioral features consistent
with autism and attention deficit hyperactivity disorder,
mild to moderate developmental delay, and language-based
learning disabilities [8]. A subset of cases also present with
microcephaly and mild dysmorphic features (e.g., elongated
face, long fingers, and joint laxity) [9, 10].
The majority of 3q29 microdeletion syndrome cases
occur de novo [11–15], which are most likely derived by
the regional low copy repeats that act as substrates for
non-allelic homologous recombination [8]. The recurrent 3q29 microdeletion spans ~ 1.6 Mb with molecular
boundaries encompassing the PAK2 and DLG1 candidate genes [8, 16]. Of note, inheritance from a mildly
affected parent has also been reported among several
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Case presentation
The 3-year-old male proband was referred to Clinical
Genetics for evaluation of a history of developmental
delay. He was the second child of non-consanguineous
parents of Mexican descent, and his pedigree was remarkable for a mother and maternal male first cousin
who required special education mainly for learning
disabilities. The prenatal history included a maternal
chlamydia infection at 3 months gestational age (treated
with antibiotics) and intrauterine growth restriction. He
was born vaginally at 37 weeks gestational age, weighing
1.98 kg, and spent a total of 23 days in the NICU requiring nasogastric feeds and phototherapy. He walked and
began to speak at 14 months of age and was subsequently diagnosed with global developmental delay by a
behavioral pediatrician. He began early intervention
services at the age of 2 years, receiving occupational,
physical and speech therapy. At 3 years of age he was
placed in special education classes getting speech and
occupational therapies. At the time of his initial genetics
evaluation, the patient could understand directions and
point to body parts. He did not know the alphabet,
colors, or numbers. In addition to these developmental
delays, the proband has a history of anemia that is

independent families, including this index case (Table 1)
[11, 14, 17–20]. This variable expression suggests that
the incidence of the 3q29 microdeletion syndrome may
potentially be higher than previously estimated (1 in
30,000-40,000) [21], as the constellation of features
among certain families may not be clinically overt.
Importantly, the 3q29 microdeletion is also one of the
largest known risk factors for schizophrenia (~ 40
fold), surpassing even the recurrent 22q11.2 microdeletion syndrome [16]. As such, accurate detection and
molecular diagnosis of the 3q29 microdeletion syndrome is critical for proper genetic counseling and
when providing neuropsychiatric risk information to
affected family members. Herein, we report a child
with global developmental delay and a chromosome
3q29 microdeletion, which subsequently was found to
be inherited from his otherwise healthy mother who
had a history of learning disabilities. This informative
case underscores the utility of CMA testing for
non-specific neurodevelopmental pediatric indications
and highlights the 3q29 microdeletion syndrome as
an illustrative example of the importance of a molecular diagnosis for pathogenic copy number aberrations with variable expressivity.

Table 1 Clinical features of inherited 3q29 microdeletion syndrome cases identified through affected probands
Current
study

Monfort et al. Ballif et al.
2008 [18]
2008 [17]

Inheritance

Maternal

Maternal

GRCh37/hg19
Position (Mb)

195.8–197.0 not provided recurrent
deletion

Maternal

Li et al.
2009 [14]

Digilio et al. Digilio et al.
2009 [19]
2009 [19]

Clayton-Smith et al. Petrin et al.
2010 [11]
2011 [20]

Paternal

Maternal

Maternal

Paternal**

recurrent deletion

195.7–197.3

Maternal

195.9–197.3 195.7–197.3 195.7–197.3

Clinical features

P1

PAR

P2

PAR

P3/4¥ PAR P5 PAR

Autistic features

–

–

–

–

+

P6 PAR

P7

PAR P8/9*

PAR

P10

PAR

–

–

–

–

–

–

–

+

–

–

–

Broad or high nasal root

+

+

+

–

+

–

–

–

–

–

–

–

+

+

+

–

Cardiac anomaly

–

–

–

+

–

–

+

+

–

–

+

–

–

–

–

–

Chest wall deformity

–

–

–

–

+

–

–

–

–

–

–

–

+

–

–

–

Cleft lip w/ or w/o cleft palate –

–

–

–

–

–

–

–

–

–

–

–

–

–

+

–

Cognitive deficit

+

–

+

+(mild)

+

–

–

–

+

–

+(mild) –

+

+

–

–

Developmental Delay

+

–

+

–

–

–

+

+(mild) –

–

+

+

+

+

+

–

Delayed language/learning

+

+

+

–

+

–

+

–

+

+(mild) +

+

+

+

–

–

Palpebral fissure defects

+

–

–

–

–

–

+

–

+

+

+

–

–

–

–

–

Ear anomalies

+

+

+

–

+

–

+

–

–

+

–

–

–

–

+

–

Feeding difficulties

–

–

–

–

–

–

–

–

–

–

+

–

–

–

–

–

GI problems

–

–

–

–

–

–

+

–

–

–

–

–

–

–

–

–

Microcephaly

–

–

–

–

+

–

–

–

+

+

+

+

+

+

–

–

+, present; −, not mentioned/evaluated; P, patient, PAR parent
¥ patients 3/4 specific clinical features were not provided; clinical features tabulated here for patients 3/4 were reported as common findings in Ballif et al. 3q29
microdeletion cohort
* patients 8/9 are siblings (maternal grandmother of P8/9, not shown in table, had the same 1.6 Mb microdeletion – noted as the 11th case of parental
transmission in a multi-generation family)
**reported as a mosaic loss in nonaffected father of proband
Coordinates of the recurrent deletion are approximately chr3:195,756,054-197,344,662 (GRCh37/hg19; ISCA region-37,443)
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followed by his pediatrician. On physical exam, the
patient was found to have a low anterior hair line. His
palpebral fissures were slightly downward slanting, and
infraorbital puffiness was noted. He has overfolded
helices bilaterally, a broad nasal bridge, a wide grin and
thin upper lip, which generally resembled the facial
features of his mother (Fig. 1).
Clinical Fragile X testing on DNA isolated from the
proband was normal with 29 CGG repeats; however,
CMA testing using the SurePrint G3 ISCA CGH + SNP
4 × 180 microarray (Agilent Technologies, Santa Clara,
CA) [22, 23] detected a heterozygous 1.21 Mb deletion
of chromosome 3q29 (reported as arr[GRCh37]
3q29(195804728_197016624)× 1) (Fig. 2). This microdeletion is smaller than the 1.6 Mb recurrent 3q29
microdeletion defined above, but still nested within its
segmental duplication boundaries (Fig. 2). It included 28
genes and transcripts, and had only minimal overlap
with copy number variants (CNVs) reported among
healthy individuals in the Database of Genomic Variants
(DGV; http://dgv.tcag.ca) [24]. The interstitial chromosome 3q29 microdeletion was confirmed using the
higher resolution CytoScan® HD platform (Affymetrix,
Santa Clara, CA) and metaphase fluorescent in situ
hybridization (FISH) using subtelomeric DNA probes
(Fig. 2). Notably, familial CMA testing determined that
the pathogenic chromosome 3q29 microdeletion was
maternally inherited and not present in the healthy older
sibling (Fig. 2), nor was it prenatally detected in a subsequent maternal pregnancy.

Discussion and conclusions
The significance of structural variation in human disease
and phenotypic diversity has increasingly become
recognized, and several genomic studies have generated
catalogs of CNVs to facilitate a better understanding of

Page 3 of 6

their clinical relevance [3, 25, 26]. It is estimated that up
to 60% of the human genome may contain structural
variants in the form of CNVs in the general population,
which typically range in size from 100 bp to 50 kb [27],
and clinical interpretation of these aberrations when
identified by CMA testing is enabled by medical genetics
practice guidelines [28]. Larger copy number aberrations
are more likely to be pathogenic, as are de novo variants;
however, large-scale genomic studies on clinically
relevant sequence variants and CNVs are increasingly
underscoring the importance and interpretation
challenges of incomplete penetrance and variable
expressivity [3, 29–31]. We report a case of the 3q29
microdeletion syndrome in a 3-year-old male with developmental delay, which was found to be inherited from
an otherwise healthy parent with a history of learning
disabilities (Table 1). This educational case is an illustrative example of the importance of a molecular diagnosis
for children with non-specific neurodevelopmental indications, particularly for families that harbor pathogenic
copy number aberrations with variable expressivity.
As indicated above, the recurrent 3q29 microdeletion
syndrome has a heterogeneous clinical phenotype, and is
enriched among young adults with psychiatric disorders
and children with developmental delay [3, 32]. In particular, mild to moderate cognitive deficits, speech delay,
low birth weight, a high nasal root, and ocular abnormalities are common findings (Table 1). Other less frequent features that can present with greater variability
include facial asymmetry, frontal bossing, large protuberant ears, upslanting palpebral fissures, broad nostrils,
and cleft lip/palate [11–15].
The 1.21 Mb deletion identified in our proband is
nested within the recurrent ~ 1.6 Mb deletion and is one
of the smallest 3q29 microdeletions reported to date
using a high-resolution CMA platform; however, it

Fig. 1 Facial features of the proband and his affected mother. Note the similar broad nasal bridge seen in both the parent and proband (a). A
closer look at the proband reveals periorbital puffiness and slightly downward slanting palpebral fissures (b). Profile views of the proband and his
mother demonstrate similar ears with an overfolded helix (c-d)
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Fig. 2 Chromosome view showing the subtelomeric 3q29 microdeletion region. Each red and blue dot represents an oligonucleotide probe
along the length of chromosome 3 with its cytobands shown on the x-axis and the log2 ratio plotted on the y-axis. The dotted lines provide a
focused view of a portion the 3q29 cytoband, annotations of UCSC genes (hg19) (http://genome.ucsc.edu/), user-defined tracks indicating the
recurrent 1.6 Mb deletion interval [(reported in [10]], and the 1.21 Mb deletion reported in our index patient. Immediately below, the presence of
copy number variants (CNVs) annotated in the Database of Genomic Variants (DGV; blue: gain; red: loss) and region-specific segmental
duplications (SDs) are shown in context (a). Zoomed-in views of chromosomal microarray (CMA) plots (X axis: hg19 genomic coordinates; Y axis:
mean log2 ratio; Agilent Technologies) depicting heterozygous copy number loss in the proband (top panel). Refinement of the deletion with a
higher resolution CMA platform (Affymetrix; bottom panel arr[GRCh37]3q29(195806608_197029439)× 1) (b). CMA plots of the mother detailing
the same heterozygous deletion as in the proband, whereas the sibling did not inherit the pathogenic chromosome 3q29 deletion (c).
Metaphase and interphase FISH specific to the subtelomeric region of chromosome 3q (D3S4560 Abbott Molecular TelVysion, red signal), and an
internal control probe specific to the subtelomeric region of chromosome 3p (D3S4559 Abbott Molecular TelVysion, green signal) in the proband.
A red signal is absent at 3q29 on one of the chromosome 3 homologs (arrow), which confirms the heterozygous deletion identified by CMA
testing (d)

directly overlaps with previously described pathogenic
deletions at this locus [21]. Additional 3q29 deletions
nested within the recurrent microdeletion have also been
described, either with a BAC or low resolution
oligonucleotide microarray platform [12, 13, 17, 33]. A
common pattern of moderate learning problems, speech
delay, psychiatric disorder, and autistic features constitutes the primary phenotypic overlap in this cohort of
smaller 3q29 deletions. A comparison of the genomic intervals between the 1.21 Mb deletion in our proband,
the previously reported smaller deletions [12, 13, 17, 33],
and the more common recurrent 1.6 Mb deletions
indicates that all include the PAK2 candidate gene. The
centromeric region of all deletions share the TFRC gene,
which is also disrupted by the deletion in our proband
and focally deleted in the recurrent deletion (Fig. 2). The
telomeric region commonly includes DLG1; however,
the recurrent larger deletions extend past DLG1 and into
BHD1 (Fig. 2). Haploinsufficiency of these genes, in
particular DLG1, has been implicated in some forms of
schizophrenia and the behavioral characteristics of the
3q29 microdeletion syndrome [16, 17, 34].
In conclusion, our case presents a set of phenotypic
features that add to the heterogeneous expression of the
3q29 microdeletion syndrome. In particular, the finding
of anemia in our proband is uncommon among reported
3q29 microdeletion syndrome cohorts; however, given
that the co-occurrence of anemia may be coincidental,
additional patients are needed to confirm whether this is
a rare feature of the 3q29 microdeletion. The familial inheritance of this pathogenic deletion and the phenotype
of the transmitting parent is summarized with other reported familial 3q29 microdeletion syndrome cases in
Table 1. Consistent among these families is a milder
phenotype in the transmitting parent, often restricted to
mild dysmorphic features and/or a history of learning/
language delays. As the landscape of genomic variation
in different populations continues to be defined, the importance of incomplete penetrance and variable expressivity are increasingly emerging. As such, the familial

inheritance of this pathogenic deletion highlights both
the clinical relevance of variable expressivity in genetic
disease and the importance of clinician awareness, particularly for inherited aberrations that also impart an increased risk for adult onset neuropsychiatric phenotypes.
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